DelveInsight’s “Cell and Gene Therapies in Rare Disorders Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the cell and gene therapies in rare disorders, historical and forecasted epidemiology as well as the Cell and Gene Therapies in Rare Disorders market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Explore the intricate details of the Gene And Cell Therapies In Rare Disorder Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Gene And Cell Therapies In Rare Disorder Market Forecast. Click here to stay ahead in healthcare innovation @ Gene And Cell Therapies In Rare Disorder Market Size

 

Key Takeaways from the Gene And Cell Therapies In Rare Disorder Market

• The total prevalent cases of selected indications for Cell and Gene Therapies in Rare Disorders in the 7MM comprised approximately 930,200 in 2023 and are projected to increase during the forecasted period.
• Among all the rare indications selected for Cell and Therapies, the highest cases were for Retinitis Pigmentosa, followed by Limbal Stem Cell Deficiency in 2023.
• In the 7MM, the total treated cases of indication-wise cell and gene therapies were approximately 504,000 in 2023, which is expected to grow during the forecast period, i.e., 2024–2034.
• The leading Gene And Cell Therapies In Rare Disorder Companies such as Pfizer/Sangamo Therapeutics, Roche (Spark Therapeutics), Pfizer/Spark Therapeutics, Freeline Therapeutics, Freeline Therapeutics, Sangamo Therapeutics, 4D Molecular Therapeutics, Spark Therapeutics (acquired by Roche), Astellas Gene Therapies, Actus Therapeutics (Acquired by Bayer), GenSight Biologics, Coave Therapeutics, Johnson & Johnson/ MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfize, Sarepta Therapeutics, Capricor Therapeutics/Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics/Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others.
• Promising Gene And Cell Therapies In Rare Disorder Therapies such as LUXTURNA (voretigene neparvovec-rzyl), ZOLGENSMA (onasemnogene abeparvovec-xioi), CARVYKTI (ciltacabtagene autoleucel), and others.

 

Delve deep into the Gene And Cell Therapies In Rare Disorder Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Gene And Cell Therapies In Rare Disorder Market Forecast. Click here to shape the future @ Gene And Cell Therapies In Rare Disorder Epidemiology Insights

 

Gene And Cell Therapies In Rare Disorder Overview

Gene and cell therapies represent advanced medical treatments that offer potential cures or significant improvements for patients with rare disorders. Gene therapy involves modifying or manipulating the genes within an individual’s cells to treat or prevent disease. For rare disorders, which are often genetic in origin, gene therapy can provide a transformative approach by targeting the root cause of the disease.

 

Gene And Cell Therapies In Rare Disorder Epidemiology Segmentation

• Total Gene And Cell Therapies In Rare Disorder prevalent cases of selected indications
• Total Gene And Cell Therapies In Rare Disorder indication-wise eligible cases
• Gene And Cell Therapies In Rare Disorder indication-wise treated cases

 

Navigate the complexities of the Gene And Cell Therapies In Rare Disorder Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Gene And Cell Therapies In Rare Disorder Market Forecast. Click here to get more insights @ Gene And Cell Therapies In Rare Disorder Treatment Market

 

Cell and Gene Therapies in Rare Disorders Marketed Drugs

• ZOLGENSMA (AVXS-101): Novartis/AveXis

ZOLGENSMA (onasemnogene abeparvovec-xioi), previously known as AVXS-101, is a proprietary gene therapy of Novartis designed for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

• LUXTURNA: Spark Therapeutics (Roche)/Novartis

LUXTURNA (AAV2-hRPE65v2), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing LUXTURNA as per a licensing agreement covering the development, registration, and commercialization rights of LUXTURNA in markets outside the US. It is indicated for the treatment of patients with vision loss due to Leber’s congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.

 

Cell and Gene Therapies in Rare Disorders Emerging Drugs

• AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics

Amicus Therapeutics is developing adeno-associated virus serotype 9 AAV9-CLN3 (AAV9-CLN3) gene therapy for children with CLN3 Batten disease. The company is leading a Phase I/IIa Gene Transfer Clinical Trial for Juvenile Neuronal Ceroid Lipofuscinosis, Delivering the CLN3 Gene by Self-Complementary AAV9. Batten disease is caused by mutations in one of 14 different genes, designated CLN1 to CLN14. The mutated gene does not work properly, ultimately leading to disease. The idea behind gene therapy is to deliver a working version of the gene into a patient’s cells — conceptually, replacing the faulty gene.

• FLT190: Freeline Therapeutics

FLT190 is a next-generation gene therapy that uses an AAV8 as a vehicle to deliver a healthy copy of the GLA gene in the hopes that it will induce the production of normal alpha-GAL A. In contrast to the regular infusions of enzyme replacement therapy (ERT), this gene therapy is designed to be given in a single dose. Preclinical data using a gene therapy platform for expressing the enzyme a-galactosidase A (GLA) has demonstrated safety and efficacy in various animal models.

• RGX-121: Regenxbio

RGX-121 is being developed as a novel, one-time treatment for MPS II, which is directly administered intra-cisternally into the CNS. It includes the NAV AAV9 vector encoding for human IDS (iduronate-2-sulfatase). Treatment with RGX-121 has been shown to restore IDS enzyme activity in animal models of MPS II to levels equivalent to or greater than those in non-affected animals. The extent of CNS correction in animal studies suggests that RGX-121 has the potential to be an important and suitable therapeutic option for MPS II patients.

 

Unlock insights into the Gene And Cell Therapies In Rare Disorder Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Gene And Cell Therapies In Rare Disorder Market Forecast. Click here @ Gene And Cell Therapies In Rare Disorder Market Drivers and Barriers

 

Gene And Cell Therapies In Rare Disorder Therapies and Companies

• LUXTURNA (voretigene neparvovec-rzyl): Spark Therapeutics/ Novartis
• ZOLGENSMA (onasemnogene abeparvovec-xioi): AveXis (Novartis)
• CARVYKTI (ciltacabtagene autoleucel): Janssen Biotech
• Fidanacogene elaparvovec: Pfizer 
• Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics
• OTL-103: Orchard Therapeutics/ SR-Tiget
• OAV101: Novartis
• TVI-Brain-1: TVAX Biomedical
• AV-GBM-1: Aivita Biomedical
• ABCB5+ MSCs: RHEACELL GmbH & Co
• CAP-1002: Capricor Therapeutics

 

Cell and Gene Therapies in Rare Disorders Market Outlook

Approval of LIBMELDY, SKYSONA, HOLOCLAR, UPSTAZA, ROCTAVIAN, and other therapies has successfully paved regulatory pathways of other cell and gene therapies currently under development. The dynamics of the cell and gene therapies market are anticipated to change as companies across the globe are thoroughly working toward the development of new cell and gene therapy options to treat a wide array of indications such as hemophilia A and B, lysosomal storage disorder (Fabry, Pompe Disease, Danon Disease, MPS I, MPS II, MPS III), neurological disorders (Batten, Parkinson), musculoskeletal disorders (DMD, myotubular myopathy, LGMD), eye diseases (achromatopsia, choroideremia, limbal stem cell deficiency, retinitis pigmentosa, retinoschisis, age-related macular degeneration, Leber’s hereditary optic neuropathy), and other indications such as diabetic macular edema, inborn metabolism disorder (Wilson’s disease, Phenylketonuria, OTC deficiency/urea cycle disorders), dystrophic epidermolysis bullosa, gangliosidosis, and xerostomia.

 

Gain a strategic edge in the Gene And Cell Therapies In Rare Disorder Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Gene And Cell Therapies In Rare Disorder Market Forecast. Click here to lead in advancements @ Gene And Cell Therapies In Rare Disorder Clinical Trials Assessment

 

Scope of the Gene And Cell Therapies In Rare Disorder Market

• Coverage- 7MM
• Gene And Cell Therapies In Rare Disorder Companies- Pfizer/Sangamo Therapeutics, Roche (Spark Therapeutics), Pfizer/Spark Therapeutics, Freeline Therapeutics, Freeline Therapeutics, Sangamo Therapeutics, 4D Molecular Therapeutics, Spark Therapeutics (acquired by Roche), Astellas Gene Therapies, Actus Therapeutics (Acquired by Bayer), GenSight Biologics, Coave Therapeutics, Johnson & Johnson/ MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfize, Sarepta Therapeutics, Capricor Therapeutics/Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics/Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others.
• Gene And Cell Therapies In Rare Disorder Therapies- LUXTURNA (voretigene neparvovec-rzyl), ZOLGENSMA (onasemnogene abeparvovec-xioi), CARVYKTI (ciltacabtagene autoleucel), and others.
• Gene And Cell Therapies In Rare Disorder Market Dynamics: Gene And Cell Therapies In Rare Disorder Market drivers and Gene And Cell Therapies In Rare Disorder Market Barriers
• Gene And Cell Therapies In Rare Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gene And Cell Therapies In Rare Disorder Unmet Needs, KOL’s views, Analyst’s views, Gene And Cell Therapies In Rare Disorder Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Key Highlights From the Report

4. Executive Summary of Cell and Gene Therapies in Rare Disorders

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Cell and Gene Therapies in Rare Disorders Market Overview at a Glance in the 7MM

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Cell and Gene Therapies in Rare Disorders: 7MM analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/